Professor, Neurology, University of Colorado School of Medicine

Neurology

Maureen A. Leehey, MD practices Neurology. She went to University of Texas Medical School. She received awards:"CMS Meaningful Use Stage 1 Certification". Maureen A. Leehey, MD is also published. She has 60 publications published. The lastest publication: "Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD.' She accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• Effect of creatine monohydrate on clinical progression in patients with Parkinson Disease: a randomized clinical trial.
• Parkinson's Disease severity and use of dopaminergic medications.
• A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit.
• Parkinsonism in fragile X-associated tremor/Ataxia syndrome (FXTAS): Revisited.
• Primary dystonia misinterpreted as Parkinson Disease: Video case presentation and practical clues.
• Memantine for fragile X-associated tremor/Ataxia syndrome: a randomized, double-blind, placebo-controlled trial.
• Emerging topics in FXTAS.
• Fragile-X-associated tremor/Ataxia syndrome (FXTAS) in females with the FMR1 premutation.
• Bell's Palsy in an older patient with uncontrolled hypertension due to medication nonadherence.
• Initial diagnoses given to persons with the fragile X associated tremor/Ataxia syndrome (FXTAS).
• PRNP H187R mutation associated with neuropsychiatric disorders in childhood and Dementia.
• Neuropathology of fragile X-associated tremor/Ataxia syndrome (FXTAS).
• Prevalence of FMR1 repeat expansions in movement disorders. A Systematic review.
• FMR1 CGG repeat length predicts motor dysfunction in premutation carriers.
• A noncanonical tertiary conformation of a human mitochondrial transfer RNA.
• Fragile X-associated tremor Ataxia syndrome in FMR1 gray zone allele carriers.
• Fibromyalgia in fragile X mental retardation 1 gene premutation carriers.
• Fragile X-associated tremor/Ataxia syndrome.
• FMR1 gray-zone alleles: association with Parkinson's Disease in women?
• AAV2-GAD gene therapy for advanced Parkinson''s Disease: a double-blind, sham-surgery controlled, randomised trial.
• Conversion disorder in women with the FMR1 premutation.
• Fragile X-associated tremor/Ataxia syndrome: clinical phenotype, diagnosis, and treatment.
• FMR1 premutation in females diagnosed with Multiple sclerosis.
• Functional status of men with the fragile X premutation, with and without the tremor/Ataxia syndrome (FXTAS).
• Transplantation.
• Treatment of fragile X-associated tremor Ataxia syndrome (FXTAS) and related neurological problems.
• The primary cognitive deficit among males with fragile X-associated tremor/Ataxia syndrome (FXTAS) is a dysexecutive syndrome.
• Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson Disease.
• Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/Ataxia syndrome.
• Neuropathy as a presenting feature in fragile X-associated tremor/Ataxia syndrome.
• Fragile X-associated tremor/Ataxia syndrome: clinical features, genetics, and testing guidelines.
• CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/Ataxia syndrome (FXTAS).
• Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ''off'' episodes in patients with Parki...
• MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?
• Fragile X syndrome vs fragile X-associated tremor/Ataxia syndrome.
• Impairment of executive cognitive functioning in males with fragile X-associated tremor/Ataxia syndrome.
• Fragile-X syndrome and fragile X-associated tremor/Ataxia syndrome: two faces of FMR1.
• Neuropathic features in fragile X premutation carriers.
• Progression of tremor and Ataxia in male carriers of the FMR1 premutation.
• Molecular and imaging correlates of the fragile X-associated tremor/Ataxia syndrome.
• Cognitive impairment in a 65-year-old male with the fragile X-associated tremor-Ataxia syndrome (FXTAS).
• Impairment in the cognitive functioning of men with fragile X-associated tremor/Ataxia syndrome (FXTAS).
• Symptomatic treatment in the fragile X-associated tremor/Ataxia syndrome.
• Size bias of fragile X premutation alleles in late-onset movement Disorders.
• Psychiatric phenotype of the fragile X-associated tremor/Ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia.
• AbNormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.
• Spastic paraparesis, cerebellar Ataxia, and intention tremor: a severe variant of FXTAS?
• Chromosome 17 and hereditary Dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD.
• Platelet mitochondrial respiratory chain function in Parkinson's Disease.
• Aging in individuals with the FMR1 mutation.
• Penetrance of the fragile X-associated tremor/Ataxia syndrome in a premutation carrier population.
• Do patients with Parkinson''s Disease benefit from embryonic dopamine cell transplantation?
• Akinetic mutism following unilateral anterior Cerebral artery occlusion.
• Tremor and Ataxia in fragile X premutation carriers: blinded videotape study.
• Fragile X premutation tremor/Ataxia syndrome: molecular, clinical, and neuroimaging correlates.
• The fragile X premutation presenting as Essential tremor.
• Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction.
• Neuronal intranuclear inclusions in a new cerebellar tremor/Ataxia syndrome among fragile X carriers.
• Intention tremor, parkinsonism, and generalized Brain atrophy in male carriers of fragile X.

Schools

---

• University Of Texas Medical School At Houston

• St Luke39s Hospital Program

• University Of Colorado University Hospital Program

• University Colo Health Science Center

Procedures Preformed

---

• EEG (Electroencephalogram)
• Non-Cosmetic Chemodenervation

Conditions Treated

---

• Alzheimer's Disease
• Ataxia
• Brain Injury
• Central Nervous System Lymphoma
• View All

Doctors Specialties

---

• Neurology

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• University of Colorado
• University of Texas Medical School

Hospital

---

• University of Colorado Hospital

Drug Facts

---

NPI NUMBER		1336258714
NPPES Provider LastName		LEEHEY
NPPES Provider FirstName		MAUREEN
NPPES Provider ZIPCode		800452545
NPPES Provider State		CO
Specialty Description		Neurology
Total Claim Count		530.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1336258714
Last Name Of The Provider	LEEHEY
First Name Of The Provider	MAUREEN
View All

Similar Doctors

---

	Dr. Timothy L. Vollmer, MD This Doctor is OpenDoctor Recommended.
	Dr. Olga S. Klepitskaya, MD This Doctor is OpenDoctor Recommended.
	Dr. Chantal M. O'Brien, MD This Doctor is OpenDoctor Recommended.
	Dr. Jonathan W. Scott, MD This Doctor is OpenDoctor Recommended.
	Dr. Brian D. Berman, MD This Doctor is OpenDoctor Recommended.
	Dr. Maria A. Nagel, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Samantha K. Holden, MD This Doctor is OpenDoctor Recommended.
	Dr. Alexander C. Mohler, MD This Doctor is OpenDoctor Recommended.
	Dr. Wayne S. Moldovan, MD This Doctor is OpenDoctor Recommended.
	Dr. Yvonne Rollins, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog